drugset
drugset / Trial / NCT00951210

Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)

NCT00951210 ↗

Phase 1 Completed 12 enrolled Pluristem Ltd.
Non-randomizedFactorialOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of PLX-PAD, Intra-muscular injections for the treatment of CLI patients.

Timeline

Start
2009-08
Primary completion
2011-01
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject EMIPLACEL Cell therapy — Intramuscular

Indications

limb ischemia peripheral arterial disease